2 

## **Trustees’ Annual Report for the period** 

**From 01/01/2025 Period start date To 31/12/2025 Period end date** 

## **Charity name: NTM NETWORK UK** 

## **Charity registration number: 1207531** 

## **Objectives and Activities** 

|**Objectves and Actvites**|||
|---|---|---|
||**SORP**<br>**reference**||
|Summary of the<br>purposes of the<br>charity as set out in its<br>governing document|Para 1.17|NTM Network UK was established in December 2014 in<br>response to the need for improved management of the rising<br>number of NTM isolates identfed in clinical practce. It<br>provides a framework within which NTM infectons and<br>disease can be systematcally investgated, researched and<br>managed.<br>NTM Network UK aims to:<br><br>Consolidate the mult-disciplinary expertse available to<br>develop standardised, cost-efectve methods and tools to<br>identfy NTM, and to improve NTM infecton and disease<br>diagnosis and management.<br><br>Standardise clinical practce and data collecton, including<br>clinical assessments, microbiology, immunology,<br>radiology, health status/quality of life scores and<br>outcomes.<br><br>Develop protocols for data collecton, clinical sampling,<br>and sample storage (to include sputum, blood, laboratory<br>and imaging data).<br><br>Obtain mult-centre ethical approval to enable data<br>collecton and long-term projects to take place.<br><br>Develop a harmonised database of NTM patents for<br>clinical use and research analysis.<br><br>Evaluate the process and outputs of the research<br>actvites.<br><br>Support new areas of research, actvites and events<br>proposed by members.<br><br>Assess and support the development of collaboratons and<br>interactons within NTM Network UK, and with other<br>research organisatons and clinical groupings.<br><br>Work to make public health surveillance of NTM more<br>robust.<br><br>Assist with resolving strategic level local and regional<br>issues and risks.|





|||<br>Support the UK patent associaton, NTM Patent Care UK,<br>in achieving its charitable aims.<br><br>Support and provide educatonal actvites in the feld of<br>NTM.|
|---|---|---|
|Summary of the main<br>actvites in relaton to<br>those purposes for the<br>public beneft, in<br>partcular, the<br>actvites, projects or<br>services identfed in<br>the accounts.|Para 1.17<br>and 1.19|_Main actvites for this reportng period include the following:_<br>a)<br>NTM Network UK has held Quarterly Members Meetngs<br>to update members on Network actvites, share reports<br>from specialist interest groups, and hear presentatons<br>from invited guest speakers. These meetngs promote<br>collaboraton, educaton, and knowledge sharing among<br>healthcare professionals involved in the care of people<br>with NTM disease.<br>b)<br>NTM Network UK has held Management Group Meetngs<br>every 6 months to review progress, oversee ongoing<br>projects, and plan future actvites in line with the charity’s<br>strategic objectves.<br>c)<br>NTM Network UK held an Annual Meetng (23/10/2025)<br>during which Network membership, output and funding<br>were all reviewed and objectves were set for the year<br>ahead<br>d)<br>NTM Network UK has produced The Patent’s Guide to<br>NTM Standards of Care in conjuncton with NTM Patent<br>Care UK<br>e)<br>NTM Network UK supported NTM research by submitng<br>a manuscript for publicaton (under review) on a Natonal<br>Audit of Clinical Practce<br>f)<br>The Pharmacy Interest Group fnalised and published the<br>NTM Monographs (htps://www.ntmnetworkuk.com/ntm-<br>drug-monographs<br>)<br>g)<br>The Extrapulmonary NTM (EPNTM) Interest Group has<br>initated a Natonal Clinical Advice Service for EPNTM<br>h)<br>The Nursing Interest Group has held regular educatonal<br>sessions to discuss complex cases as well as providing<br>advice and peer support<br>i)<br>Across these actvites, NTM Network UK has aimed to<br>improve outcomes for people with NTM disease in the UK,<br>by strengthening collaboraton between healthcare<br>professionals, promotng consistency and quality in clinical<br>care, and supportng educaton and research.|





|Statement confrming<br>whether the trustees<br>have had regard to<br>the guidance issued<br>by the Charity<br>Commission on public<br>beneft|Para 1.18|The trustees have had regard to the Charity Commission’s<br>guidance on public beneft.|
|---|---|---|



## **Additional information (optional)** 

You may choose to include further statements where relevant about: 

||**SORP**<br>**reference**||
|---|---|---|
|Policy on grant<br>making|Para 1.38|N/A|
|Policy on social<br>investment<br>including program<br>related investment|Para 1.38|N/A|
|Contributon made<br>by volunteers|Para 1.38|All actvites undertaken by NTM Network UK during the<br>reportng period were delivered through the work of volunteers.<br>The Network’s members, including clinicians, pharmacists,<br>scientsts, and other healthcare professionals, contributed their<br>tme and expertse for free in developing the materials produced<br>by NTM Network UK. The charity’s ability to deliver these<br>outputs relies entrely on the ongoing commitment and goodwill<br>of its volunteer members.|
|Other||N/A|



## **Achievements and Performance** 

||**SORP**<br>**reference**||
|---|---|---|
|Summary of the main<br>achievements of the charity,<br>identfying the diference the<br>charity’s work has made to<br>the circumstances of its<br>benefciaries and any wider<br>benefts to society as a<br>whole.|Para 1.20|_Main achievements for this reportng period include the_<br>_following:_<br>a)<br>NTM Network UK has produced The Patent’s Guide<br>to NTM Standards of Care in conjuncton with NTM<br>Patent Care UK<br>b)<br>NTM Network UK has developed patent and<br>clinician checklists covering new diagnosis and<br>outpatent management<br>c)<br>Development of scientfc abstracts to share fndings<br>with the wider healthcare community, including<br>analysis of the use of bedaquiline in NTM treatment|





- d) Publication of detailed NTM Monographs by the Pharmacy Interest Group, offering practical guidance for clinicians and pharmacists in the effective use of NTM treatments (htps://www.ntmnetworkuk.com/ntm-drugmonographs). 

## **Additional information (optional)** 

You may choose to include further statements where relevant about: 

|Achievements against objectves set|Para 1.41|N/A|
|---|---|---|
|Performance of fundraising actvites against objectves set|Para 1.41|N/A|
|Investment performance against objectves|Para 1.41|N/A|
|Other||N/A|



## **Financial Review** 

|Review of the charity’s fnancial<br>positon at the end of the<br>period|Para<br>1.21|The charity is in positve balance.<br>The charity did not carry forward any income or expenses<br>from theprevious NTM Network UK actvites|
|---|---|---|
|Statement explaining the policy<br>for holding reserves statng<br>why they are held|Para<br>1.22|The Charity has no policy for holding reserves and a policy<br>is not considered necessary at this tme as the charity<br>contnued to require limited spending during this<br>reportng period.|
|Amount of reserves held|Para<br>1.22|NA|
|Reasons for holding zero<br>reserves|Para<br>1.22|The charity has had very limited spending over the<br>reportng period, so reserves are not considered<br>necessary.|
|Details of fund materially in<br>defcit|Para<br>1.24|N/A|
|Explanaton of any<br>uncertaintes about the charity<br>contnuingas agoingconcern|Para<br>1.23|N/A|



## **Additional information (optional)** 

You may choose to include further statements where relevant about: 

|The charity’s principal<br>sources of funds<br>(includingany|Para<br>1.47|The charity had a positve balance of £15,581.34 at the end of this<br>period. Income had been received via fundraising undertaken by<br>members of the NTM Network undertakingsponsored events. We|
|---|---|---|





|fundraising)||received £4500 from the pharmaceutcal company Shionogi B.V in<br>support of our Annual Meetng which enabled us to invite world-<br>leading experts in NTM to partcipate in a panel discussion|
|---|---|---|
|Investment policy and<br>objectves including<br>any social investment<br>policyadopted|Para<br>1.46|N/A|
|A descripton of the<br>principal risks facing<br>the charity|Para<br>1.46|N/A|
|Other||N/A|



## **Structure, Governance and Management** 

|**Structure, Governance and Management**|||
|---|---|---|
|Descripton of charity’s trusts:||N/A|
|Type of governing document<br>(trust deed, royal charter)|Para<br>1.25|Consttuton of the Charitable<br>Incorporated Organisaton (CIO)|
|How is the charity consttuted?<br>(e.g unincorporated associaton, CIO)|Para<br>1.25|Charitable Incorporated Organisaton<br>(CIO)|
|Trustee selecton methods including details of<br>any consttutonal provisions e.g. electon to post<br>or name of any person or body enttled to<br>appoint one or more trustees|Para<br>1.25|Trustees include founding individuals<br>and healthcare professionals, to ensure<br>the best representaton of professionals<br>in NTM care.|



## **Additional information (optional)** 

You may choose to include further statements where relevant about: 

|**Additonal informaton (optonal)**<br>You maychoose to include further statements where relevant about:|||
|---|---|---|
|Policies and procedures adopted for the inducton and training of trustees|Para<br>1.51|N/A|
|The charity’s organisatonal structure and any wider network with which the<br>charity works|Para<br>1.51|N/A|
|Relatonship with any related partes|Para<br>1.51|N/A|
|Other||N/A|



## **Reference and Administrative details** 

|Charityname|**NTM Network UK**|
|---|---|
|Other name the charity<br>uses|**N/A**|





|Registered charity<br>number<br>Charity’s principal<br>address|**1207531**|
|---|---|
||**Royal Free London NHS Foundaton Trust, Pond St, Hampstead, London**<br>**NW3 2QG**|



## **Names of the charity trustees who manage the charity during period of report** 

|**Trustee Name**|**Ofce (if any)**|**Dates acted if not for**<br>**whole year**|**Name of person (or**<br>**body) enttled to**<br>**appoint trustee (if**<br>**any)**|
|---|---|---|---|
|Marc Lipman|Trustee|||
|Ronan Breen|Trustee|||
|Ibrahim Abubakar|Trustee|||
|Jennie Keane|Trustee|||
|Lisa Morrison|Trustee|||



Corporate trustees – names of the directors at the date the report was approved 

**Director name N/A** 

Name of trustees holding title to property belonging to the charity 

|**Trustee name**<br>**N/A**|**Dates acted if not for wholeyear**||
|---|---|---|
||||



## **Funds held as custodian trustees on behalf of others** 

|Descripton of the assets held in this capacity<br>Name and objects of the charity on whose behalf the assets are held and how this falls within<br>the custodian charity’s objects<br>Details of arrangements for safe custody and segregaton of such assets from the charity’s<br>own assets|N/A|
|---|---|
||N/A|
||N/A|



## **Additional information (optional)** 

## **Names and addresses of advisers (Optional information)** 

|**onal informaton (optonal)**<br>**Names and addresses of advisers (Optonal informaton)**|**onal informaton (optonal)**<br>**Names and addresses of advisers (Optonal informaton)**|
|---|---|
|**Type of adviser**<br>**Name**<br>**Address**||
||**Type of adviser**<br>**Name**<br>**Address**|
||N/A|





**Name of chief executive or names of senior staff members (Optional information) N/A** 

## **Exemptions from disclosure** 

Reason for non-disclosure of key personnel details 

## **N/A** 

**Other optional information N/A** 

## **Declarations** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

**Signature(s) Full name(s)** Ronan Angus MacCormick Breen **Position (eg Secretary, Chair, etc)** Vice-Chair **Date** 31/10/2026 

